These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10756332)

  • 1. A novel heparin/protamine-based pro-drug type delivery system for protease drugs.
    Liang JF; Song H; Li YT; Yang VC
    J Pharm Sci; 2000 May; 89(5):664-73. PubMed ID: 10756332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.
    Liang JF; Li YT; Connell ME; Yang VC
    AAPS PharmSci; 2000; 2(1):E7. PubMed ID: 11741223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.
    Liang JF; Park YJ; Song H; Li YT; Yang VC
    J Control Release; 2001 May; 72(1-3):145-56. PubMed ID: 11389993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.
    Liang JF; Li YT; Song H; Park YJ; Naik SS; Yang VC
    J Control Release; 2002 Jan; 78(1-3):67-79. PubMed ID: 11772450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis.
    Absar S; Choi S; Ahsan F; Cobos E; Yang VC; Kwon YM
    Thromb Res; 2013 Mar; 131(3):e91-9. PubMed ID: 23269380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of "ATTEMPTS" for drug delivery.
    Naik SS; Liang JF; Park YJ; Lee WK; Yang VC
    J Control Release; 2005 Jan; 101(1-3):35-45. PubMed ID: 15588892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
    Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
    J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prodrug approach for delivery of t-PA: construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct.
    Song H; Liang JF; Yang VC
    ASAIO J; 2000; 46(6):663-8. PubMed ID: 11110262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules.
    Absar S; Nahar K; Choi S; Ahsan F; Yang VC; Kwon YM
    J Biomed Mater Res A; 2014 Aug; 102(8):2481-90. PubMed ID: 23946132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis.
    Absar S; Choi S; Yang VC; Kwon YM
    J Control Release; 2012 Jan; 157(1):46-54. PubMed ID: 21930168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid molecules: insights into plasminogen activator function.
    Runge MS; Bode C; Haber E; Quertermous T
    Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery system for targeted thrombolysis without the risk of hemorrhage.
    Byun Y; Yang VC
    ASAIO J; 1998; 44(5):M638-41. PubMed ID: 9804513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for improving the functionality of an affinity bioreactor.
    Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC
    Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrin targeting of echogenic liposomes with inactivated tissue plasminogen activator.
    Klegerman ME; Zou Y; McPherson DD
    J Liposome Res; 2008; 18(2):95-112. PubMed ID: 18569446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects.
    Park YJ; Liang JF; Song H; Li YT; Naik S; Yang VC
    Adv Drug Deliv Rev; 2003 Feb; 55(2):251-65. PubMed ID: 12564979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effector roles of kringle 1 and kringle 2 in the enzymatic properties of recombinant tissue-type plasminogen activator as revealed by generation of recombinant molecules containing each kringle linked to the protease domain.
    Rydzewski A; Castellino FJ
    Arch Biochem Biophys; 1993 Jan; 300(1):472-82. PubMed ID: 8424682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.
    Runge MS; Bode C; Matsueda GR; Haber E
    Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7659-62. PubMed ID: 3118374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery.
    Murray TG; Jaffe GJ; McKay BS; Han DP; Burke JM; Abrams GW
    Refract Corneal Surg; 1992; 8(1):44-8; discussion 48-53. PubMed ID: 1554639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
    Chang LC; Lee HF; Chung MJ; Yang VC
    Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified dextran, heparin-based triggered release microspheres for cardiovascular delivery of therapeutic drugs using protamine as a stimulus.
    Nguyen HX; O'Rear EA
    J Microencapsul; 2017 May; 34(3):299-307. PubMed ID: 28436713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.